SAB Biotherapeutics Files 8-K on Director/Officer Changes & Shareholder Votes
Ticker: SABSW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-appointment, director-election, shareholder-vote
TL;DR
SAB Biotherapeutics filed an 8-K covering director changes, officer appointments, and shareholder votes.
AI Summary
On September 26, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure and election of directors, as well as the appointment of certain officers and compensatory arrangements. Additionally, the report covers the submission of matters to a vote of security holders and the filing of financial statements and exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and governance, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic decisions that may carry inherent risks.
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former Company Name
- September 26, 2025 (date) — Date of Report
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
Who are the newly elected directors or appointed officers?
The filing mentions the election of directors and appointment of officers, but their names are not specified in the provided text.
What are the details of the compensatory arrangements for the officers?
The filing notes compensatory arrangements for certain officers, but the specific terms and amounts are not detailed in this excerpt.
What financial statements and exhibits are being filed?
The filing states that financial statements and exhibits are being filed, but their specific content is not described in the provided text.
When did SAB Biotherapeutics, Inc. change its name from Big Cypress Acquisition Corp.?
SAB Biotherapeutics, Inc. changed its name from Big Cypress Acquisition Corp. on November 20, 2020.
Filing Stats: 864 words · 3 min read · ~3 pages · Grade level 12.9 · Accepted 2025-09-26 16:45:39
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
Filing Documents
- sabs-20250926.htm (8-K) — 62KB
- sabs-ex10_1.htm (EX-10.1) — 243KB
- 0001193125-25-220721.txt ( ) — 484KB
- sabs-20250926.xsd (EX-101.SCH) — 46KB
- sabs-20250926_htm.xml (XML) — 6KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The total number of shares of Common Stock entitled to vote at the Special Meeting was 11,099,061 shares (on an as-converted to Common Stock basis), consisting of 10,411,061 shares of Common Stock outstanding as of the record date and 688 shares of Series A Preferred Stock, par value $0.0001 per share outstanding and entitled to vote as of the record date ("Series A Preferred Stock"). There were 6,053,045 shares present in person or by proxy at the Special Meeting, which represented approximately 54.5% of the outstanding shares entitled to vote at the Special Meeting (including shares of Series A Preferred Stock on an as-converted basis) and which constituted a quorum for the transaction of business. At the Special Meeting, the stockholders voted to: (1) approve the potential issuance in excess of 19.99% of the Company's outstanding Common Stock upon the conversion of the Company's Series B Convertible Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock"), at less than the "minimum price" under Nasdaq Listing Rule 5635(d), and which may deemed a "change of control" under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock governing the Series B Preferred Stock (the "Series B Nasdaq Conversion Proposal"); and (2) approve the Plan Amendment to, among other things, (i) increase the maximum number of shares of Common Stock available to Plan participants thereunder by 24,180,000 shares to an aggregate of 31,932,466 shares, and (ii) increase the maximum number of additional shares available for issuance pursuant to the annual evergreen increase from 10,000,000 shares to 73,750,000 shares. The voting results on these proposals were as follows: Proposal 1: Approval of Series B Nasdaq Conversion Proposal Votes For Votes Against Abstentions 5,502,026 515,275
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1 Amended and Restated 2021 Omnibus Equity Incentive Plan, as amended 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: September 26, 2025 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer